AbSano

AbSano is a biotechnology company focused on the discovery and development of next-generation antibody therapeutics. Spun out from the University of Texas at Austin and co-founded by renowned researcher George Georgiou, the company utilizes a proprietary platform to identify high-affinity antibodies directly from the human immune repertoire. By leveraging high-throughput sequencing and advanced bioinformatics, AbSano aims to develop treatments for challenging targets in oncology, infectious diseases, and inflammatory conditions. The company's approach focuses on capturing the natural diversity of the human immune response to create more effective and safer biologic drugs.